MEDICLIN AG / Key word(s): Forecast/Annual Results MEDICLIN raises full-year guidance for the 2024 financial year 21-Jan-2025 / 16:36 CET/CEST Disclosure of an inside information
Issuer: Mainz BioMed N.V. / Key word(s): Study 21.01.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed
DocMorris AG / Key word(s): Development of Sales DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter 21.01.2025 /
EQS-News: Marinomed Biotech AG / Key word(s): Insolvency/Restructure of Company Marinomed Biotech AG: Restructuring proceedings successfully completed 20.01.2025 / 07:45 CET/CEST The issuer is solely
EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and
EQS Newswire / 17/01/2025 / 10:07 UTC+8 The concept of value investing always withstands the test of time, and CK Life Sciences has demonstrated exceptional
Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Drägerwerk AG & Co. KGaA: Preliminary figures 2024: Net sales just below and earnings just
New York, 01/15/2025 / 09:15, EST/EDT – EQS Newswire – Laxxon Medical Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced
Issuer: Goldinvest Consulting GmbH / Key word(s): Miscellaneous/Product Launch 15.01.2025 / 09:46 CET/CEST The issuer is solely responsible for the content of this announcement. Canadian
EQS-News: Cantourage Group SE / Key word(s): Development of Sales Legalization of cannabis brings strong growth: Cantourage Group SE increases its sales by 118% to